＜4922＞KOSE 8084 -519

A sharp decline. Jeffries Securities downgraded investment decisions from “hold” to “underperform,” and the target stock price was also raised from 10,000 yen to 7500 yen. There is a high possibility that sales levels in China and South Korea will fall significantly below 2022, and it is expected that there will be a large disparity in cosmetics operating profit compared to the same year level. It is also difficult to anticipate an increase in domestic margins, and they seem to think that consensus profit forecasts are dependent on excessive expectations.

＜7846＞pilot 4516 +294

Massive backlash. Nomura Securities has made a new “buy” investment decision, and the target stock price is 5400 yen. By developing overseas markets centered on competitive products such as the erasable ballpoint pen “Friction” and the gel ink ballpoint pen “G-2,” it seems to be evaluated that growth is expected over the medium to long term. Overseas sales are expected to grow at an annual rate of about 6% in the future, and it also seems that the annual operating profit increase rate is also expected to be in the latter half of the 10% range for the fiscal year ending 26/12.

＜6005＞Miura Takumi 3445 +208

Significant continued growth. SMBC Nikko Securities continued the investment decision “1,” and raised the target stock price from 4700 yen to 5,000 yen. PER is at a record low level, and it was determined that there is a strong sense of undervaluation, and while there is a strong sense of uncertainty about the performance of cyclical stocks, the purchase recommendation was once again emphasized as a defensive stock. Short-term loans have increased as bridge loans, and there are concerns about finance risks, but the company has clearly stated loan procurement, and uncertainty will gradually be dispelled over the next fiscal year.

＜9692＞CEC 1711 -132

The sharp decline continued. Financial results for the first half of the year were announced the day before. Operating income was 3.25 billion yen, down 7.8% from the same period last year, and although the previous forecast of 3.16 billion yen was up, profit began to decline from the same 4.2% increase in the first quarter. The full year plan is 6.28 billion yen, and the 1.3% decrease from the previous fiscal year remains unchanged. Along with the increase in DX demand, both main businesses and focus businesses have been on a steady trend, but it seems that an increase in growth investments such as research and development costs, recruitment activity costs, and education expenses was a factor in the decline in profit.

＜6769＞zine 1515 +300

The stop is high. It has been announced that an ultra-high speed PAM4 64 Gbps communication optical semiconductor chipset compatible with the next-generation communication standard PCI Express 6.0 for data server data transmission has been realized. The chipset is the world's first VCSEL-compatible optical semiconductor that does not require an optical communication DSP with high power consumption, and it is expected that the effect of reducing the power consumption of optical communication lines by 60% and reducing delays caused by optical DSP processing to zero.

＜2695＞ Kura Sushi 3475 -150

The sharp decline continued. Financial results for the 3rd quarter were announced the day before, and cumulative operating income was 6.36 billion yen, an improvement of 6.74 billion yen compared to the same period last year, greatly exceeding the full-year forecast of 5.5 billion yen. However, the May-July fiscal year was 0.72 billion yen, down 10.4% from the same period, and profit growth slowed. The consensus level also appears to have declined slightly. It seems that the pace of increase in sales in the US is slowing down as business confidence deteriorates. Furthermore, it seems that the upward trend in full-year results itself has already been factored in.

＜9675＞ Tokiwa 1676 +136

Significant continuous growth. Fortress Investment's Ontario, which is a US investment fund, has announced that it will implement TOB with the aim of making it a wholly owned subsidiary. The company expresses opinions in support and says that applications are recommended. The TOB price is 1650 yen, and although observation reports were reported the day before and it ended at a high stop, it is a premium of about 30% from the level before the rapid increase. Note, today they are being bought to a level slightly above TOB prices.

＜3180＞ B Garage 1569 +122

Massive backlash. Financial results for the first quarter were announced the day before, and although operating profit was 0.32 billion yen, down 18.0% from the same period last year, a temporary increase in sales and administration costs such as exhibition costs and third DC related expenses was a factor, and negative reactions remained limited. Meanwhile, movements that look positively at 0.16 million shares, which is 1.26% of the number of issued shares, announcements of company stock buybacks with an upper limit of 0.2 billion yen, and announcements of the start of ID cooperation with Recruit's “Air Business Tools” are dominant.

＜2163＞ Altner 1857 +105

Massive backlash. Financial results for the first half of the year were announced the day before, and operating profit was 0.96 billion yen, up 8.9% from the same period last year, and it looks like it will turn from a 0.6% decrease in the first quarter to an increase in profit. The full-year forecast of 1.7 billion yen, an 11.4% increase from the previous fiscal year, remained unchanged. In addition to the increase in the number of engineers, the operating rate also remained at a high level, and it also seems that the unit price for engineers is above the same period last year. Due to the effect of increasing sales, it seems that advance investments such as costs related to expansion of training facilities and recruitment-related investment costs have been covered.

＜4568＞ Daiichi Sankyo 5275 +-499

A sharp decline. New data from a phase 3 clinical trial targeting secondary/tertiary treatment for non-small cell lung cancer was presented at the World Lung Cancer Society for datopotamab deluxtecan. The results seem to be mixed, but the partner AstraZeneca declined when the data was announced, and it looks like sales are ahead of the company. The median overall survival, which is one of the main evaluation items, showed an improvement trend for the docetaxel administration group, but it seems that no statistically significant improvement was observed.